Kyowa Kirin Approves Up To $530M Investment To Build New Biologics Plant In Sanford, NC

Kyowa Kirin, Inc., a global specialty pharmaceutical company, is investing $530 million to construct a new biologics manufacturing facility in Sanford, North Carolina. The facility will focus on developing and producing biologic therapies for rare and serious diseases, addressing the unmet needs of patients worldwide. With construction set to begin in the second half of 2024 and full operation expected by 2027, the facility will create over 100 new jobs and bolster Kyowa Kirin's global manufacturing network. This investment is supported by both state and local incentives. Continue reading to learn about the plans for this new, state-of-the-art manufacturing plant.